The article deals with the case of correction of antipsychotic therapy with unexplained anxiety in a patient with schizotypal disorder based on found mutations in GST-M1 and GST-T1 genes, which indicate that glutathione-S-transferase enzymes have been impaired, which is the cause of non-specific endogenous intoxication by active metabolites of antipsychotics and the development of drug induced akathisia, which may be manifested by subjective complaints of anxiety spectrum.

1. Jablensky A. (2000) Epidemiology of schizophrenia: the global burden of disease and disability. Eur Arch Psychiatry ClinNeurosci. Vol. 250, no. 6, pp. 274–285.

2. Gerlach J, Peacock L.(1995) New antipsychotics: the present status. In ClinPsychopharmacol. Vol. 10, pp. 39–48.

3. Steck H. (2006) Extrapyramidal and diencephalic syndrome in the course of largactil and serpasil treatments. Ann Med Psychol (Paris). Vol. 12, pp. 737–744.

4. Poyurovsky M (2010). Acute antipsychotic-induced akathisia revisited. Br J Psychiatry. Vol. 196, no. 2, pp. 89–91.

5. Plotnikova E. V. (2009) Lekarstvenno-inducirovannye dvigatel'nye rasstrojstva pri shizofrenii. Tavricheskij mediko-biologicheskij vestnik. T. 12, № 1 (45). S. 192–199.

6. Sachdev P (2004) Early extrapyramidal side-effects as risk factors for later tardive dyskinesia: a prospective study. Aust N Z J Psychiatry. Vol. 38, no. 6, pp. 445–9.

7. Duncan E. J., Adler L. A., Stephanides M. et al. (2000) Akathisia and exacerbation of psychopathology: a preliminary report. ClinNeuropharmacol. Vol. 23, pp. 169–173.

8. PeitlM. V., ProloščićJ., Blažević-ZelićS. (2011) Et al. Symptoms of agitated depression and/or akathisia. Psychiatr Danub. Vol. 23, no. 1, pp.108–110.

9. Reid A. M., McNamara J. P, Murphy T. K. (2015) Sideeffects of SSRIs disrupt multimodal treatment for pediatric OCD in a randomized-controlled trial. J Psychiatr Res. Vol. 71, pp. 140–147.

10. Lipinski J. F. Jr., Mallya G., Zimmerman P. et al.(1989) Fluoxetine-induced akathisia: clinical and theoretical implications. J Clin Psychiatry. Vol. 50, no. 9, pp. 339–342.

11. Temmingh H., Stein D. J. (2015) Anxiety in Patients with Schizophrenia: Epidemiology and Management. CNS Drugs. Vol. 29, no. 10, pp. 819–832.

12. Kim JH, Byun HJ (2009). Non-motor cognitiveperceptual dysfunction associated with drug-induced parkinsonism. Hum Psychopharmacol. Vol. 24, no. 2, pp. 129–134.

13. Kim JH, Kim SY, Byun HJ (2008). Subjective cognitive dysfunction associated with drug-induced parkinsonism in schizophrenia. Parkinsonism Relat. Disord. Vol. 14, no. 3, pp. 239–242.

14. Lohr J. B., Eidt C. A., Abdulrazzaq Alfaraj A. et al. (2015) The clinical challenges of akathisia. CNS Spectr. 20 Suppl 1:1–14; quiz 15–16.

15. Berrios G. E. (1995) Lad Haskovec and akathisia: an introduction. Hist Psychiatry. 6 (22 Pt 2):243–251.

16. Pae CU, Yu HS, Kim JJ, Kim W, Lee CU, Lee SJ, Jun TY, Lee C, Paik IH, Serretti A. (2004) Glutathione S-transferase M1 polymorphism may contribute to schizophrenia in the Korean population. Psychiatr Genet.14:147-150.

17. Белоусов Ю. Б., Кукес В. Г., Лепахин В. К., Петров В. И. (2009) Клиническая фармакология: национальное руководство. – М.: ГОЭТАР-Медиа. – С. 854–868.

18. Nnadi CU, Malhotra AK. (2007) Individualizing antipsychotic drug therapy in schizophrenia: the promise of pharmacogenetics. Curr Psychiatry Rep. 9(4):313-318.